FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1001794971> ?p ?o ?g. }

• W1001794971 endingPage "4485" @default.
• W1001794971 startingPage "4485" @default.
• W1001794971 abstract "Abstract Background. Peripheral T-cell lymphomas (PTCLs) originate from post-thymic T cells but compared to B-cell lymphomas the exact cell of origin is usually unknown except for angioimmunoblastic T-cell lymphoma arising from a follicular helper T-cell. Furthermore, no recurrent cytogenetic or molecular abnormalities are identified in PTCLs. Recently, recurrent impairment of the p53 pathway has been pointed out in PTCLs. However, p53 knockout (KO) mice are known to develop immature thymic T-cell lymphomas and solid tumors but surprisingly PTCLs have not been reported for more than 20 years in those mice. NKT cells are a T-cell subset responsive to glycolipids presented by CD1d, a major histocompatibility complex (MHC) class I-like antigen-presenting molecule, in contrast to conventional T cells, which recognize peptide antigens. Two types of NKT cells have been described so far: type I or invariant NKT cells (iNKT) that express a Valpha14-Jalpha18 (in mice) or Valpha24-Jalpha18 (in humans) constant chain and type II NKT cells that express a variable TCR but are CD1d-dependent as well. Most type II NKT cells are of alpha/beta phenotype but CD1d-restricted gamma/delta T cells have also been described in mice and humans. Methods. The development of PTCLs in p53 KO mice (B6.129S2-Trp53tm1Tyj/J) was studied. Identification of PTCLs was made by immunohistochemistry and flow cytometry analysis. Gene expression profile analysis (GeneChip Mouse Genome 430 2.0 array, Affymetrix) was performed to characterize lymphomas developed in the mouse model. Transfer experiments were done by intravenously retro-orbital injection into syngeneic, immunocompetent C57Bl/6J WT animals or immunocompromised CD3ε-/- mice. Therapeutic trials in mice were performed with the use of blocking anti-CD1d monoclonal antibodies (mAb) (clone HB323; BioXcell). Results. We found that p53 KO mice developed well-known and characterized thymic T-cell lymphomas and solid tumors as previously described. However, about 20% of p53 KO mice spontaneously developed a previously unrecognized entity of PTCLs originating from CD1d-restricted iNKT cells (ie type I NKT cells) referred to as NKTLs for NKT lymphomas thereafter. Both alpha-galactosylceramide-CD1d tetramer staining and unique Valpha14-Jalpha18 TCR rearrangement confirmed the iNKT nature of these lymphomas. Chronic injection of Streptococcus pneumoniae (Spn), reported to express glycolipid antigens activating NKT cells, significantly increased the incidence of these NKTLs compared to a control group of p53 KO mice injected with PBS (P=0.03). Gene expression profile analysis indicated a significant down-regulation of genes in the TCR signaling pathway of NKTLs (false discovery rate q-value=0.01 by gene set enrichment analysis) suggesting an underlying antigenic chronic stimulation as previously reported in chronically activated T cells (Figure 1). Moreover, NKTLs were characterized by upregulation of PD-1 and loss of NK1.1 expression compared to resting NKT cells (P<0.01 for both), which are features of activated and anergic iNKT cells. Altogether, those data indicate that NKTLs in mice could arise from chronically activated iNKT cells by endogenous or exogenous glycolipids. Furthermore, in vivo TCR/CD1d interactions were required for NKTLs survival after transfer in recipient mice and the use of blocking anti-CD1d mAb significantly prolonged mice overall survival (logrank P<0.001, Figure 2). We did not identify human PTCLs arising from type I iNKT cells by using alphaGalCer-CD1d tetramer staining. However, using sulfatide-loaded CD1d tetramers (ie another type of glycolipid-CD1d tetramer identifying type II NKT cells), we identified CD1d-restricted human PTCLs among gamma/delta hepatosplenic T-cell lymphomas (HSTLs) and PTCL-not otherwise specified (PTCL-NOS) expressing the Vd1 TCR but not the Vd2 TCR (Figure 3). Conclusion. This demonstrates for the first time the existence of human PTCLs arising from gamma/delta CD1d-restricted type II NKT cells. These results refine the classification of PTCLs in humans by identifying a new cell of origin and pave the way for the development of blocking anti-CD1d antibodies for therapeutic purposes. Figure 1. Figure 1. Figure 2. Figure 2. Figure 3. Figure 3. Disclosures No relevant conflicts of interest to declare." @default.
• W1001794971 created "2016-06-24" @default.
• W1001794971 creator A5004249491 @default.
• W1001794971 creator A5004594498 @default.
• W1001794971 creator A5008006641 @default.
• W1001794971 creator A5012900514 @default.
• W1001794971 creator A5014727099 @default.
• W1001794971 creator A5019387967 @default.
• W1001794971 creator A5021242485 @default.
• W1001794971 creator A5023137852 @default.
• W1001794971 creator A5023625996 @default.
• W1001794971 creator A5024323677 @default.
• W1001794971 creator A5042899914 @default.
• W1001794971 creator A5045374333 @default.
• W1001794971 creator A5046761978 @default.
• W1001794971 creator A5048916540 @default.
• W1001794971 creator A5053019069 @default.
• W1001794971 creator A5058603550 @default.
• W1001794971 creator A5059858110 @default.
• W1001794971 creator A5060085776 @default.
• W1001794971 creator A5064856085 @default.
• W1001794971 creator A5073629929 @default.
• W1001794971 creator A5075530519 @default.
• W1001794971 creator A5086354986 @default.
• W1001794971 date "2014-12-06" @default.
• W1001794971 modified "2023-10-18" @default.
• W1001794971 title "Identification of Previously Unrecognized CD1d-Restricted Peripheral T Cell Lymphomas (PTCLs) in Mouse and Human Reveals Blocking Anti-CD1d Monoclonal Antibodies As a New Therapeutic Possibility in PTCLs" @default.
• W1001794971 doi "https://doi.org/10.1182/blood.v124.21.4485.4485" @default.
• W1001794971 hasPublicationYear "2014" @default.
• W1001794971 type Work @default.
• W1001794971 sameAs 1001794971 @default.
• W1001794971 citedByCount "0" @default.
• W1001794971 crossrefType "journal-article" @default.
• W1001794971 hasAuthorship W1001794971A5004249491 @default.
• W1001794971 hasAuthorship W1001794971A5004594498 @default.
• W1001794971 hasAuthorship W1001794971A5008006641 @default.
• W1001794971 hasAuthorship W1001794971A5012900514 @default.
• W1001794971 hasAuthorship W1001794971A5014727099 @default.
• W1001794971 hasAuthorship W1001794971A5019387967 @default.
• W1001794971 hasAuthorship W1001794971A5021242485 @default.
• W1001794971 hasAuthorship W1001794971A5023137852 @default.
• W1001794971 hasAuthorship W1001794971A5023625996 @default.
• W1001794971 hasAuthorship W1001794971A5024323677 @default.
• W1001794971 hasAuthorship W1001794971A5042899914 @default.
• W1001794971 hasAuthorship W1001794971A5045374333 @default.
• W1001794971 hasAuthorship W1001794971A5046761978 @default.
• W1001794971 hasAuthorship W1001794971A5048916540 @default.
• W1001794971 hasAuthorship W1001794971A5053019069 @default.
• W1001794971 hasAuthorship W1001794971A5058603550 @default.
• W1001794971 hasAuthorship W1001794971A5059858110 @default.
• W1001794971 hasAuthorship W1001794971A5060085776 @default.
• W1001794971 hasAuthorship W1001794971A5064856085 @default.
• W1001794971 hasAuthorship W1001794971A5073629929 @default.
• W1001794971 hasAuthorship W1001794971A5075530519 @default.
• W1001794971 hasAuthorship W1001794971A5086354986 @default.
• W1001794971 hasConcept C107006841 @default.
• W1001794971 hasConcept C139563560 @default.
• W1001794971 hasConcept C147483822 @default.
• W1001794971 hasConcept C153911025 @default.
• W1001794971 hasConcept C167672396 @default.
• W1001794971 hasConcept C195616568 @default.
• W1001794971 hasConcept C203014093 @default.
• W1001794971 hasConcept C2778607024 @default.
• W1001794971 hasConcept C2779338263 @default.
• W1001794971 hasConcept C37386791 @default.
• W1001794971 hasConcept C502942594 @default.
• W1001794971 hasConcept C86803240 @default.
• W1001794971 hasConceptScore W1001794971C107006841 @default.
• W1001794971 hasConceptScore W1001794971C139563560 @default.
• W1001794971 hasConceptScore W1001794971C147483822 @default.
• W1001794971 hasConceptScore W1001794971C153911025 @default.
• W1001794971 hasConceptScore W1001794971C167672396 @default.
• W1001794971 hasConceptScore W1001794971C195616568 @default.
• W1001794971 hasConceptScore W1001794971C203014093 @default.
• W1001794971 hasConceptScore W1001794971C2778607024 @default.
• W1001794971 hasConceptScore W1001794971C2779338263 @default.
• W1001794971 hasConceptScore W1001794971C37386791 @default.
• W1001794971 hasConceptScore W1001794971C502942594 @default.
• W1001794971 hasConceptScore W1001794971C86803240 @default.
• W1001794971 hasIssue "21" @default.
• W1001794971 hasLocation W10017949711 @default.
• W1001794971 hasOpenAccess W1001794971 @default.
• W1001794971 hasPrimaryLocation W10017949711 @default.
• W1001794971 hasRelatedWork W1001794971 @default.
• W1001794971 hasRelatedWork W146728918 @default.
• W1001794971 hasRelatedWork W2023401063 @default.
• W1001794971 hasRelatedWork W2095967285 @default.
• W1001794971 hasRelatedWork W2103768147 @default.
• W1001794971 hasRelatedWork W2147816683 @default.
• W1001794971 hasRelatedWork W2326295882 @default.
• W1001794971 hasRelatedWork W2517554569 @default.
• W1001794971 hasRelatedWork W2783697011 @default.
• W1001794971 hasRelatedWork W74318593 @default.
• W1001794971 hasVolume "124" @default.
• W1001794971 isParatext "false" @default.
• W1001794971 isRetracted "false" @default.
• W1001794971 magId "1001794971" @default.
• W1001794971 workType "article" @default.